Date Published
Country
Source
Reports
close
- 1643 results found
-
Negative Innovation: When Patents are Bad for Patients
Incentives in patent law have driven innovation into spaces that are afrmatively harmful to patients, and patentees are discouraged from taking steps to improve the product so as to prevent adverse health outcomes. -
Rx Drugs: A Personal Option
Price controls are deeply flawed and cause far more harm than good. Invariably, they cause scarcity, lead to bureaucratic rationing, and, perversely, drive up real prices by spawning inefficient black markets.Comments
No comments yet. Create an account and log in to post a comment.
-
ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s disease.Comments
No comments yet. Create an account and log in to post a comment.
-
FDA Allows Drugs Without Proven Clinical Benefit to Languish for Years on Accelerated Pathway
Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent approval of aducanumab (Aduhelm) for dementia.Comments
No comments yet. Create an account and log in to post a comment.
-
What is the Evidence on Legal Measures to Improve the Transparency of Markets for Medicines, Vaccines and Other Health Products (World Health Assembly resolution WHA72.8)?
Health Evidence Network Synthesis Report 73Comments
No comments yet. Create an account and log in to post a comment.
-
7 Ways Drug Pricing Legislative Proposals Would Lower Costs for Consumers and Businesses
This issue brief outlines just some of the ways that drug pricing reform would help consumers and businesses.Comments
No comments yet. Create an account and log in to post a comment.
-
ICER Releases Draft Evidence Report on Therapies for Myasthenia Gravis
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of eculizumab and efgartigimod for the treatment of myasthenia gravis.Comments
No comments yet. Create an account and log in to post a comment.
-
Indication-Based Pricing - Consultation Report
Should drug prices differ by indication?Comments
No comments yet. Create an account and log in to post a comment.
-
Divergent Spender: State- Societal and Meso- Organisational Mechanisms in the Containment of Public Spending on Pharmaceuticals in a Liberal Capitalist Democracy
An interesting look at New Zealand's 'unique drug agency' - the Pharmaceutical Management Agency (PHARMAC) - and important lessons U.K. policymakers can learn if prices for therapies and access to key drugs are to be protected.Comments
No comments yet. Create an account and log in to post a comment.
-
Tramadol: Where Do We Go From Here?
The history of tramadol is relatively young compared to other prescription medications. The drug was developed in 1962 by the drug company Grünenthal GmbH that specializes in treating pain.Comments
No comments yet. Create an account and log in to post a comment.
-
How High Drug Prices Hurt Black Americans
Racial inequity penetrates every corner of the American health care system, and high prescription drug prices are no exception.Comments
No comments yet. Create an account and log in to post a comment.
-
Statement for Hearing on “A Prescription for Change: Cracking Down on Anticompetitive Conduct in Prescription Drug Markets”
Submitted to the Senate Committee on the Judiciary Subcommittee on Competition Policy, Antitrust, and Consumer RightsComments
No comments yet. Create an account and log in to post a comment.
-
What’s Yours is Ours: Waiving Intellectual Property Protections for COVID-19 Vaccines
Ethical arguments for temporarily waiving IP protections for COVID-19 vaccines begin by showing why arguments to the contrary fall short.Comments
No comments yet. Create an account and log in to post a comment.
-
Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs
An interesting new look at the interplay on the activities and policies of the drug industry and its stakeholders.Comments
No comments yet. Create an account and log in to post a comment.
-
ICER Publishes Evidence Report on Therapies for Atopic Dermatitis
For treating atopic dermatitis, health-benefit price benchmarks for these therapies range from $21,400 to $41,800 per year; upadacitinib requires the steepest discount - 35-63% - off its list price to reach common thresholds for cost-effectiveness.Comments
No comments yet. Create an account and log in to post a comment.
Comments